State Street Corp Metacrine, Inc. Transaction History

State Street Corp

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$0.43 - $0.57 $31,039 - $41,146	-72,186 Closed	0 $0
Q2 2022 Aug 15, 2022	BUY	$0.36 - $0.63 $21,528 - $37,674	59,800 Added 482.8%	72,186 $36,000
Q1 2022 May 16, 2022	BUY	$0.43 - $0.7 $765 - $1,246	1,781 Added 16.79%	12,386 $8,000
Q2 2021 Aug 16, 2021	SELL	$3.37 - $5.73 $242,724 - $412,703	-72,025 Reduced 87.17%	10,605 $40,000
Q1 2021 May 17, 2021	BUY	$6.2 - $11.0 $54,727 - $97,097	8,827 Added 11.96%	82,630 $512,000
Q4 2020 Feb 16, 2021	BUY	$7.75 - $11.42 $571,973 - $842,830	73,803 New	73,803 $580,000

Ticker MTCR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,569,500
Description
Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

Stay updated on State Street Corp with notifications on news.